To determine if RR-MS is associated with alterations in peripheral inflammatory signature, we initially assessed plasma levels of the inflammatory chemokine IL-8 and cytokine TNF-α in plasma from control and RR-MS groups. This evidence concerns the gene CXCL8 and myeloid sarcoma.